T h e ne w e ngl a nd jou r na l o f m e dicine H irschsprung's disease is characterized by the lack of ganglia in the myenteric and submucosal plexuses of the gut. It is a "model" complex disorder because it exemplifies multifactorial inheritance and yet has been molecularly tractable. [1] [2] [3] The disease (with an incidence of 15 cases per 100,000 live births) is characterized by high heritability (>80%) and marked sex differences (male:female ratio, 4:1). 2 Patients have aganglionosis affecting bowel segments of variable length, as a result of incomplete rostral-to-caudal enteric neuronal colonization; on the basis of these segment lengths, the condition is classified as short, long, or total colonic aganglionosis (see the Supplementary Appendix, available with the full text of this article at NEJM .org). Approximately 18% of patients have multiple anomalies, some with specific syndromes; approximately 12% have major chromosomal variants. 2, 3 Features of Hirschsprung's disease include its high (3 to 17%) sibling recurrence risk (i.e., the risk of being born with the disease, given that one full sibling is affected) and the variation in risk according to sex, segment length, and familiality. 2 Hirschsprung's disease has multifactorial causes, although no environmental causes are known. 4, 5 Complex segregation analyses have refined this view by showing genetic heterogeneity according to the extent of aganglionosis. The long form is characterized by autosomal dominant inheritance and the short form by recessive or multifactorial inheritance, and the variants associated with both forms have incomplete penetrance. 6 This finding led to the discovery of 17 genes with approximately 500 rare disease-associated coding variants, chiefly the genes encoding the receptor tyrosine kinase RET and the G-proteincoupled receptor EDNRB (Table S1 in the Supplementary Appendix) . 3, [7] [8] [9] [10] [11] [12] [13] Four noncoding variants, individually conferring moderate risks (odds ratio, 1.6 to 3.9) but together conferring risk that can vary by as much as a factor of 30 with increasing risk-allele dosage, 13 are genetic modifiers of Hirschsprung's disease. 11, 14 These data suggest widespread and variable genetic susceptibility to the disease from multiple genes, reflected in the differing presentations and recurrence risks among relatives.
We suspected that, in contrast to the genetic risk factors for other complex diseases, many genetic risk factors make individually large contributions to the risk of Hirschsprung's disease.
We undertook genotyping, exome-sequencing, and functional assays to study pathogenic alleles in a set of patients with Hirschsprung's disease with representative phenotypes. Beyond studying known genes and identifying new ones, we investigated the variation in risk according to the type of pathogenic allele, the contribution of each type of allele to Hirschsprung's disease in the general population, and the distribution of these types of alleles across phenotypes. Our primary goal was to enable genetic stratification of patients in order to determine how genetic susceptibility manifests in clinical disease and its penetrance. Such genetic stratification could be used to determine whether postsurgical outcome -for example, continued bowel dysfunction and enterocolitis, which is reported in 30 to 50% of patients 15, 16 -is related to genotype.
Me thods

Participants and Genomewide Analyses
We conducted exome sequencing of samples from 190 patients of European ancestry and 47 of their affected relatives (7 parents, 12 children, 17 siblings, and 11 second-degree relatives) with diverse phenotypes. The control sample used in exome sequencing consisted of publicly available, ancestry-matched exome data on 740 samples from the 1000 Genomes Project and the National Institute of Mental Health Repository. For the analysis of common noncoding variant studies, we used a different set of 627 control samples that were genotyped in our laboratory: 404 from the 1000 Genomes Project and an additional 223 "pseudocontrols" (generated from the chromosomes not transmitted to the affected child in 254 parentchild trios 13 ). For the analysis of copy-number variants, we used a third control set of 19,584 adults of European ancestry. 17 Sequence variants, genotypes and their frequencies at single-nucleotide variants, small (<50 bp) insertions or deletions, and copy-number variants were identified and annotated. [17] [18] [19] [20] [21] Single-nucleotide polymorphism (SNP) arrays were used to validate copy-number variant calls. Genotype calls at transcription-enhancer variants were from our previous studies involving the same study population. 13, 22 The sample ascertainment and analysis methods are described in detail in the Methods section, Tables S1 through S5, and Figures S1 through S3 in the Supplementary Appendix.
Genetic Anatomy and Risk Profile of Hirschsprung's Disease
Pathogenic Alleles, Genes, and Loci For assessing the effect of common noncoding variants, we used four disease-associated SNPs -rs2435357, rs7069590, and rs2506030 in RET and rs11766001 in the SEMA3 gene cluster. 13, 22 We have previously shown that the RET noncoding variants are located within transcription enhancers bound by the transcription factors RARB, GATA2, and SOX10; these variants lead to reduced RET expression and an elevated risk of Hirschsprung's disease. 22 Although the causality of the rs11766001 polymorphism in the SEMA3 locus is unproven, considerable data support causality or a strong association with a causal variant in SEMA3C or SEMA3D, which have been shown to be necessary for gut innervation. 12, 13 Coding pathogenic alleles at each gene were defined as nonsense or missense changes in codons encoding amino acids that are conserved (with respect to their position in the oligopeptide) across species, splice-site single-nucleotide variants, and all coding insertion-deletion variants with a frequency of 5% or less. These definitions gave acceptable levels of true and false positives at known Hirschsprung's disease genes (Table S1 in the  Supplementary Appendix). 23 Disease-associated coding variants can have incomplete penetrance and be present in controls; therefore, we identified Hirschsprung's disease-associated genes as those that had a greater number of unique pathogenic alleles in patients than in controls (Fig. S4 in the Supplementary Appendix). We assessed large copy-number variants (deletions of more than 500 kb and duplications of more than 1 Mb) with a frequency of less than 1% among controls to determine whether they were significantly enriched among patients or had previously been found to be associated with a developmental disorder (Tables S8 and S9 and Fig. S5 in the Supplementary Appendix). 17, 24 Additional details are provided in the Methods section in the Supplementary Appendix.
To assess the role of a gene in Hirschsprung's disease, we first used reverse-transcriptase polymerase chain reaction (RT-PCR) to assess its RNA expression in the human embryonic gut at Carnegie stage 22, by which time gut neurogenesis is complete (Fig. S6 in 12 The sequence data generated as part of this study are available in the National Center for Biotechnology Information (NCBI) database of Genotypes and Phenotypes (dbGaP) under accession number phs000497. The RNA sequencing data used in this study are accessible under NCBI Gene Expression Omnibus (GEO) accession number GSE99232.
Statistical Analysis
Population-level risks were estimated for groups of pathogenic alleles, genes, or loci with the use of odds ratios with significance thresholds (corrected for multiple testing) and 95% confidence intervals. 13, 25 The odds ratios were converted to estimated population penetrance (equivalent to the population incidence or risk) with Bayes' theorem, under the assumption of an incidence of 15 cases per 100,000 European-ancestry live births.
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Allele frequencies among controls were obtained from a variety of public resources 17, 21, 26 to estimate the population attributable risk. Additional details are provided in the Methods section in the Supplementary Appendix.
R esult s
Common Regulatory Variants and Risk
Four common transcription-enhancer variants were associated with a moderate risk of Hirschsprung's disease in our sample of 190 patients and 627 controls (Table S2 in the Supplementary Appendix). [9] [10] [11] [12] [13] The frequency of these variants allowed us to estimate their total effect according to dosage in reference to persons with one allele (none had zero alleles): a risk of Hirschsprung's disease (odds ratio >1) is evident only with three or more alleles ( T h e ne w e ngl a nd jou r na l o f m e dicine cording to enhancer risk-allele dosage, which shows the wide differences in basal susceptibility to Hirschsprung's disease.
Risk Associated with Rare Coding Variants
We first tested whether coding pathogenic alleles, as we defined them, for the 17 known Hirschsprung's disease genes statistically discriminated patients from controls (Table S1 in the Supplementary Appendix). As compared with the 29 pathogenic alleles found in 71 (9.6%) of 740 controls, 36 pathogenic alleles were found in 41 (21.6%) of 190 patients, a percentage 2.25 times as high (P = 5.97×10 −6 ) ( Table S6 in the Supplementary Appendix), which indicates a higher burden of pathogenic alleles in patients. Furthermore, the pathogenic alleles that were found in patients had a significantly lower mean frequency in an external reference population, the Exome Aggregation Consortium database 21 (ExAC), than did the pathogenic alleles found in controls (5.58×10 −4 vs. 1.11×10 −3 , P = 2.14×10 −5 ) ( Table S6 in the Supplementary Appendix), which indicates that the rare coding changes observed in patients have been subject to greater purifying selection than those observed in controls. That is, even though pathogenic alleles in both patients and controls met our definition of pathogenicity, when we compared the frequency of each set (variants in the patients being one set and variants in the controls the other) with the frequency of the specific variants of each set in persons in the ExAC database, those of the patient set were less frequent in the ExAC database than were those in the control set.
To assess the enrichment of pathogenic alleles for each gene, we estimated the probability (P value) of finding as many or a greater number of distinct pathogenic alleles in patients, restricting our analysis to 15,963 single-nucleotide variants in 4027 genes for which there was at least one identified pathogenic allele in both patients and controls. We identified 3 genes, EDNRB, ADAMTS17, and ACSS2, that exceeded the significance threshold of 1.24×10 −5 (5% significance across 4027 genes) (Fig. S4 in the Supplementary Appendix). More broadly, at a P value threshold of 0.001, we found 10 genes instead of the expected 4 (P = 1.3×10 −3 ) ( Table 3) . We performed functional tests on these 10 genes to distinguish false from true candidates.
The top 10 genes had a minimum of 4 pathogenic alleles each and included both of the major genes, RET and EDNRB. We also found evidence of 7 novel Hirschsprung's disease genes -ACSS2, ADAMTS17, ENO3, FAM213A, SH3PXD2A, SLC27A4, and UBR4 -on the basis of both an excess of pathogenic alleles and enteric nervous system gene expression in humans and mice during enterogenesis; assays in zebrafish further confirmed ACSS2, , respectively, a difference similar in magnitude to the difference we observed for alleles in the 17 previously known Hirschsprung's disease genes. The causality of these variants is further confirmed by higher-than-expected genotype concordance between probands with coding pathogenic alleles and their affected relatives (P = 0.005) (Tables S6  and S7 and the Methods section in the Supplementary Appendix).
Pathways and Functional Groups
Owing to genetic heterogeneity and chance fluctuations, the overall contribution of pathways to Hirschsprung's disease can be estimated more accurately than that of individual genes (Table  S7 in the Supplementary Appendix). In Hirschsprung's disease, the RET and EDNRB signaling pathways play major roles with strong epistatic interactions. 7, 8, 11 Thus, we considered members of the RET (GDNF, NRTN, GFRA1, and RET) and EDNRB (ECE1, EDN3, and EDNRB) signaling modules for burden analysis. A third pathway, also epistatic to RET, involves the class 3 semaphorins and their receptors: here we consider only SEMA3C and SEMA3D because of their association with Hirschsprung's disease. 12, 13 A fourth class consists of the transcription-factor genes (SOX10, ZEB2, PHOX2B, and TCF4) that are critical to the early development of the enteric nervous system and harbor rare coding variants that cause Hirschsprung's disease-associated syndromes (Table S1 in the Supplementary Appendix). We considered two additional categories: other known genes (KIF1BP, L1CAM, IKBKAP, and NRG1) 3, 10 and the seven novel genes identified in this study. 9.1 * Although the differences were not significant, the odds ratios in males were consistently larger than those in females (Table S10 in the Supplementary Appendix). † The combined population attributable risk for all three classes of pathogenic alleles, under the assumption of independent effects, is 61.9%
for all 24 known and novel loci and 53.7% for the 18 known loci. ‡ Five or more common disease variants were observed in 90 of 186 patients and 107 of 627 controls. § Rare coding sequence variants were identified in 66 of 190 patients and in 37 of 740 controls. ¶ The copy-number variants (CNV) that were considered to be pathogenic, as reported in this table and in all our other analyses of risk, were clinically identified alterations (e.g., trisomy 21 or 22q deletion) or deletions of more than 500 kb or duplication of more than 1000 kb, with a frequency of less than 1% among controls, that had previously been significantly associated with a developmental disorder. CNVs were identified in 21 of 185 patients and in 40 of 19,584 controls. ‖ The only copy-number variant that was previously known to be associated with Hirschsprung's disease was trisomy 21. 
We compared the total numbers of pathogenic-allele genotypes in each of these six classes or pathways among the 66 variant-positive patients with their corresponding frequencies among controls (Table S7 in the Supplementary Appendix). Genes encoding members of the EDNRB pathway (odds ratio, 69.03; 95% CI, 8.68 to 547.92), transcription-factor genes (odds ratio, 35.73; 95% CI, 4.15 to 307.72), and novel genes (odds ratio, 23.2; 95% CI, 11.04 to 48.72) had the largest risk effects, followed by genes encoding members of the RET pathway (odds ratio, 16.03; 95% CI, 5.21 to 49.28) and SEMA3C and SEMA3D (odds ratio, 2.65; 95% CI, 1.25 to 5.60). Other known genes (odds ratio, 3.15; 95% CI, 1.22 to 8.09) also made measurable risk contributions, but with an order of magnitude smaller effect. These risk rankings were reflected in the inverse contributions of these classes to the total risk of Hirschsprung's disease. Pathogenic alleles causing greater risk probably have higher penetrance and are therefore selected against with greater intensity. If so, the abundant coding variants in genes of the RET pathway have lower penetrance than coding variants in the genes of the EDNRB pathway, the genes encoding transcription factors, and the novel genes.
These data also indicate that RET has a smaller coding-variant risk burden than previously believed: 6.3% of the patients (12 patients) had RET coding pathogenic alleles, in contrast to approximately 50% from the older data. 2, 7 This difference could arise from differing definitions of pathogenicity or from the preponderance of familial and severe cases in earlier studies. Nevertheless, RET regulatory pathogenic alleles, which have even lower penetrance than coding pathogenic alleles, 9 were prevalent and, together with RET coding variants, conferred substantial risk in 92 of 190 patients (48.4%); this finding highlights the fact that reduced RET expression is the predominant cause of Hirschsprung's disease. Moreover, coding or noncoding (in the case of RET transcription-enhancer variants) pathogenic alleles in affecting genes that encode members of the RET regulatory network, 22 which is made up of RET, its transcription factors (RARB, GATA2, and SOX10), its ligands (GDNF and NRTN), and its coreceptor (GFRA1), were found in 120 of our patients (63.2%). In contrast, genes of the EDNRB pathway contributed to only 8 cases (4.2%).
Frequency of Copy-Number Variants in Hirschsprung's Disease
Of the 190 patients, 17 (8.9%) had syndromic presentations or known major chromosomal variants (Table 4) . To detect subkaryotypic changes, we examined the exome data to identify large copy- Yes Yes Yes * The human embryonic gut samples were evaluated at Carnegie stage 22, and mouse embryonic gut samples were evaluated at embryonic day 10.5. † NT indicates that the gene was not tested owing to a lack of an identifiable zebrafish orthologue. ‡ The number of distinct pathogenic alleles was significant after multiple-test correction for 4027 genes. number variants. In total, we identified 16 distinct copy-number variants; 14 of these variants (and their loci) were not previously known to be associated with Hirschsprung's disease (Table 4) . We assessed the pathogenicity of each variant on the basis of its enrichment in patients or their association with a known developmental disorder to identify 9 chromosomal variants and copynumber variants in 11.4% of patients (21 of (Tables 2 and 4, and Table S9 in the Supplementary Appendix). 2, 3, 6 Of the 21 instances of pathogenic chromosomal variants in patients, 18 (86%) were recurrent and 3 were nonrecurrent, and 18 were in patients with syndromic presentations (Table S9 in the Supplementary Appendix). The most frequent (11 variants, 52%) recurrent finding was trisomy 21, but the other 7 occurred at well-known loci for other genomic disorders. The elevated fre- for whom we did not have a submitted karyotype. ‡ The control data are from the study by Coe et al. 17 ; however, the numbers for the variant 47,XX,+der (15)t(4:15) are for the two duplications at the translocation site, not for the translocation, and the control numbers were not available and not expected for the 10q24.3-q26.13 inversion. § The variant had previous evidence of pathogenicity in another developmental disorder. ¶ The number was estimated from population data (Table S8 in the Supplementary Appendix). ‖ The P value was significant after multiple-test correction. ** The 13q21.33-q31.1del CNV deletes EDNRB. T h e ne w e ngl a nd jou r na l o f m e dicine quency of trisomy 21 among patients with Hirsch sprung's disease (odds ratio, 73.69; 95% CI, 34.97 to 155.29; P = 1.23×10 −29 ) (Table 2) is not surprising, given previous observations. 14 However, the 16p11.2del copy-number variant, which is usually associated with autism, 27 is also significantly enriched (odds ratio, 30.03; 95% CI, 9.70 to 92.97; P = 3.62×10 −9 ). Overall, the 9.7% frequency of patients with Hirschsprung's disease who have recurrent chromosomal variants is significantly higher than the expected frequency (odds ratio, 53.30; 95% CI, 30.30 to 93.76; P = 2.60×10 −43 ). These recurrent chromosomal changes are known to be associated with intellectual disability, autism, neurodevelopmental delay, epilepsy, and Charcot-Marie-Tooth disease type 1A, 27, 28 perhaps owing to pathways common to the enteric and central nervous systems. The three nonrecurrent variants, one of which deletes EDNRB, were unique, and all occurred in patients with syndromic presentations (Table 4) .
Distribution of Diverse Pathogenic Alleles
Pathogenic alleles in at least 32 genes and loci contribute to Hirschsprung's disease: rare coding variants in 24 genes, common noncoding variants at four sites within 2 loci, and large copy-number variants and chromosomal anomalies in at least 8 additional loci (not including 13q21.33-q31.1del, which overlaps EDNRB). The common noncoding risk genotypes (five or more risk alleles), rare coding variants, and copy-number variants occur at decreasing (by orders of magnitude) frequencies in the general population -17.1%, 5.0%, and 0.2% -but with increasing odds ratios of 4.54, 10.02, and 63.07, respectively (Table 2 ). In consequence, all three variant classes make major contributions to the risk of Hirschsprung's disease, with population attributable risks of 37.7%, 31.1%, and 11.3%, respectively, and a total attributable fraction of 61.9%. In addition, although the differences are not significant, the odds ratios among males are consistently higher than those among females (Table S10 in the Supplementary Appendix). Thus, the sex effect in Hirschsprung's disease is not caused by a specific gene or variant but is a property of the disorder. We conclude that, first, even in this rare disorder, common variants are responsible for the majority of cases of Hirschsprung's disease, despite their individually lower risks, because of their high population prevalence. Second, the total risk from all rare coding pathogenic alleles (which have a much higher penetrance) is also high but is differentially spread over 24 genes. Third, the population risk from copy-number variants is the lowest, spread over the effects of 9 loci but with a majority contribution from trisomy 21. These risks from both known and novel genes and loci are almost certainly overestimates owing to the "winner's curse." Consequently, we reestimated the risks, taking into consideration only the well-established risk factors and genes known before this study, and we found the same pattern: these variant classes occur at frequencies of 17.1%, 3.9%, and 0.1% in the general population, but with increasing risks -odds ratios of 4.54, 6.70, and 73.69, respectively ( Table 2 ). These three categories contribute to the population attributable risks of 37.7%, 18.2%, and 9.1%, respectively, or a total attributable fraction of 53.7%.
Finally, we quantified the risk associated with combinations of pathogenic alleles (Table S11 in the Supplementary Appendix). 29 We classified each patient's total burden of pathogenic alleles according to sex, segment length, familiality, and the presence or absence of additional anomalies; we pooled all patients with copy-number variants into one class, given the low frequency of this type of variant. The results showed three cardinal features (Table 5) . First, genetic risk factors of any type were identifiable in 72.1% of patients, and patients harbored various combinations of different types of pathogenic alleles, all in significant excess relative to controls. Second, each of the three variant classes (five or more common noncoding variants, rare coding variants, and copy-number variants) were present in substantial percentages of diagnoses (48.4%, 34.7%, and 11.4%, respectively) ( Table 2) . One, two, or three different classes of molecular lesion were present in 51.9%, 18.4%, and 1.7% of patients, respectively -roughly their expected frequencies -with no evidence of interaction, a finding consistent with multifactorial expectations, although the statistical power for such detection is probably low (Table 5, and Table S11 in the Supplementary Appendix). Third, the genotypespecific odds ratios for Hirschsprung's disease, estimated in reference to the class with no identifiable genetic risk factor, vary by a factor of 67 and increase with the pathogenic allele burden. These data allow us to estimate the absolute risk of Hirschsprung's disease, given a person's geno- We did not detect any significant genotypephenotype associations with respect to sex, segment length, familiality, or syndromic status. However, patients with a copy-number variant and patients with both a common transcriptionenhancer risk genotype and a rare coding variant -the two classes with the highest relative risks -are characterized by an excess representation of males and of nonfamilial cases. The sex ratio in classes with no evident pathogenic alleles or those with rare coding single-nucleotide variants only is approximately 1. This latter class is most often seen in persons with an affected relative (familial disease), which suggests that most segregating pathogenic alleles in affected families are rare coding variants. There was also a greater tendency for Hirschsprung's disease to be syndromic among patients in higher risk classes than among those in lower risk classes.
Discussion
Hirschsprung's disease can arise both from lowpenetrance genetic disorders 2, [6] [7] [8] and from highpenetrance monogenic syndromes. 2, 3 Risk prediction and genetic counseling therefore depend on family history, risk factors (sex and segment length), and targeted assessment for syndromic features. 6 Thus, in a small subset of patients, classical genetic testing of RET, EDNRB, and genes that are associated with syndromes may be informative. The results reported here, however, suggest that widespread genomic analyses may be useful for clinical research and improved risk stratification.
Hirschsprung's disease is usually an isolated condition and unassociated with family history. However, genetic causal factors can be identified in approximately 72% of cases, for which molecular class, frequency, and disease risk can be quantified on the basis of sequence data alone, explaining between 53.7% and 61.9% of population attributable risk. Approximately 21% of patients have multiple risk factors, with the genotype-specific incidence increasing by a factor of more than 100 (risk ranging from approximately 1 in 18,800 to 1 in 120) as the number of genotypic risk factors increases from zero to three. Therefore, we have sufficient quantification of disease risk according to genotype to address questions of underlying causes and genetic architecture and to provide genetic counseling for the highest-risk 21% of patients and their relatives.
We have made considerable strides in understanding the functional basis of Hirschsprung's disease. The majority of the 32 genes and loci are known to have roles in the development of the enteric nervous system. In contrast, the majority of patients (63.2%) have identifiable pathogenic alleles only within the known RET regulatory network, which lead to decreased RET signaling. The RET effect is potentially even larger, affecting 78.9% of patients, because an additional 5.8% of patients harbor pathogenic alleles in UBR4, a novel E3 ligase gene identified in this study and a candidate for RET signal termination; 5.9% of patients have trisomy 21, which results in an elevated dosage of SOD1, encoding a negative regulator of RET 14 ; and 4.2% of cases involve EDNRB, which is SOX10-regulated. 30, 31 Thus, genetic testing of at least the RET regulatory network is warranted for risk stratification.
In order to understand the biology of enteric nervous system cell proliferation, migration, colonization, and neuronal specialization, it is important to understand the steps subsequent to the transition and differentiation of enteric nervous system cells, such as the likely axonal guidance functions of SEMA3C and SEMA3D. 12 The seven novel genes identified here, all of which are expressed in the human gut at the appropriate developmental stages, probably control some aspects of axonal guidance, cell proliferation, and local inflammation (Table S12 in the Supplementary Appendix). We hypothesize that screening the genes regulating these processes in early gut development will further resolve the remaining approximately 40% of Hirschsprung's disease risk.
A continuing challenge in the study of Hirschsprung's disease is to understand the cellular mechanisms underlying the disease. Whether we consider the persons with the highest (1 in 120) or lowest (1 in 18,800) risk, the absolute risk of disease is still small. What are the cellular events that trigger or prevent aganglionosis, given a par- 29 (81) 18 (58) 30 (83) 21 ( = 0.67; 1 df; P = 0.41). § Hirschsprung's disease is classified as short, long, or total on the basis of the length of bowel segment affected. ¶ A simplex case is one in which the patient has no known family members with the disease. ‖ Category includes patients with five or more common noncoding risk alleles at RET (rs2435357, rs2506030, and rs7069590) and SEMA3D (rs11766001). ** A coding variant was considered to be present if the patient had at least one rare, deleterious variant found in any of the 24 Hirschsprung's disease susceptibility genes. † † The CNVs that were considered to be pathogenic, as reported in this table and in all our other analyses of risk, were clinically identified alterations (e.g., trisomy 21 or 22q deletion) or deletions of more than 500 kb or duplication of more than 1000 kb, with a frequency of less than 1% among controls, that had previously been associated with a developmental disorder. All patients with CNVs were pooled into one class, given the low frequency of this type of variant. ‡ ‡ Percentages were calculated with 179 used as the denominator (i.e., the patients with complete data for all three mutation classes). § § Expected values are calculated from the frequencies of each risk class among controls (see Table 2 ).
ticular genotype? A part of the answer is the existence of very rare de novo gene mutations affecting the enteric nervous system, 32 which require larger cohorts of trios for the detection of an association. However, the incomplete penetrance of most Hirschsprung's disease variants implies that stochastic, environmental, or epigenetic factors must be important.
In our study, we found that the risk of the complex phenotype that is Hirschsprung's disease stemmed from a combination of variants in numerous genes and different classes of genetic variants: noncoding variants, single-nucleotide variants and copy-number variants, and both rare and common variants. Despite the current thinking in human medical genetics, most of the risk of Hirschsprung's disease arose from a common widespread genetic susceptibility, on top of which rare coding and rarer copy-number variants exacerbated the risk. Despite this molecular diversity, the implicated genes clustered, on the basis of their known function, into gene regulatory networks (which, in Hirschsprung's disease, regulate the transition from enteric neural-crest cells to enteric neuroblasts, axonal guidance, and neuroblast proliferation), a model that may be relevant to the understanding of other complex disorders.
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